Summary of BrightSpring Health Services Conference Call Company Overview - BrightSpring Health Services is a leading provider of home and community healthcare services in the U.S. [2] - The company serves approximately 400,000 individuals daily, focusing on high-quality, impactful services [3][4]. Business Segments Pharmacy Platform - The pharmacy platform includes closed-door home and community pharmacy services, specialty pharmacy, and infusion services [3]. - BrightSpring processes over 40 million prescriptions annually, catering to patients with specialized needs [3]. - The specialty pharmacy and oncology business have been significant growth drivers, with expectations of 20%+ growth [11][9]. Provider Platform - The provider platform encompasses home health, rehab, hospice, and personal care services [4]. - The company anticipates a growth rate of 12% to 15% for its provider business this year [9]. - The integration of services allows for better coordination of care, reducing hospitalizations by 50% [4]. Primary Care Platform - The primary care platform focuses on home-based primary care, enhancing care coordination for patients with multiple chronic conditions [30][32]. - The company has entered into value-based care arrangements, showing a 10% to 15% cost reduction with improved outcomes [33]. Financial Performance - BrightSpring has achieved a historical revenue and EBITDA CAGR of 15%, with recent acceleration towards 30% growth this year [7][10]. - The company aims to maintain a mid-teens growth rate moving forward [10]. M&A Strategy - BrightSpring has a history of small tuck-in acquisitions, averaging 10 to 15 deals annually, primarily in the $10 to $15 million EBITDA range [38][41]. - The company has successfully completed 68 deals historically, with a high success rate in increasing EBITDA post-acquisition [41]. Balance Sheet and Deleveraging - The company expects to exit 2025 with a leverage ratio of around 3x, targeting 2x by 2026 [36][43]. - Positive cash flow generation supports deleveraging efforts, with potential for increased acquisition activity in 2026 [36]. Regulatory Environment - BrightSpring is actively engaging with payers regarding potential reimbursement changes due to the IRA, with expectations of manageable impacts [46][48]. - The company anticipates that home health reimbursement will eventually align with the ROI of home health services [48]. Key Takeaways - BrightSpring's integrated service model across pharmacy, provider, and primary care enhances operational efficiencies and patient outcomes [49]. - The company's focus on scale, quality, and technology positions it well within the growing home and community healthcare market [2][4]. - BrightSpring's strategic approach to M&A and capital deployment aims to sustain growth while maintaining a healthy balance sheet [38][43].

Core Insights - BrightSpring Health Services, Inc. (NASDAQ:BTSG) is recognized as one of the 11 best-performing IPOs in the last two years, with a significant price target elevation by analysts following a strong second quarter performance and improved revenue and adjusted EBITDA guidance [1][2]. Financial Performance - The company reported a 29% year-over-year revenue growth, reaching $3.1 billion for Q2 2025 [2]. - Revenue in its Pharmacy Solutions segment grew by 32% year-over-year, with specialty scripts increasing by 38% [2]. - Following this performance, the company raised its revenue and adjusted EBITDA guidance for 2025, indicating a positive outlook [2]. Analyst Ratings and Price Targets - Analysts have raised their price targets for BTSG, with Deutsche Bank increasing it from $25 to $30 and Bank of America from $27.50 to $31 [3]. - The consensus rating for the stock remains a Buy, reflecting strong market confidence [3]. Company Background - BrightSpring Health Services, Inc. was founded in 1974 and is headquartered in Kentucky, specializing in home and community-based health and pharmacy services for individuals with complex health needs [4]. Stock Performance - Since its IPO, BTSG has demonstrated significant growth, with a total growth percentage of 147.09% to date [3].

Core Viewpoint - BrightSpring Health Services Inc. (NASDAQ:BTSG) is identified as a strong growth stock under $30, with a recent price target increase from BofA to $31, maintaining a Buy rating despite concerns over a more negative policy and reimbursement environment [1][3]. Financial Performance - In Q2 2025, BrightSpring Health reported total revenue of $3.1 billion, reflecting a 29% year-over-year increase [2]. - Adjusted EBITDA also increased by 29% to $143 million, while the EBITDA margin remained flat at 4.5% compared to the previous year [2]. - Gross profit for the quarter was $375 million, marking a 20% increase [2]. Segment Performance - The Pharmacy Solutions segment was the main growth driver, with revenue rising 32% year-over-year to $2.8 billion [3]. - Infusion and Specialty Revenue within this segment saw a significant 39% increase, reaching $2.2 billion, while specialty scripts grew by 38% [3]. - Home & Community Pharmacy Revenue grew by 11% to $587 million, contributing to the overall growth in gross profit per script [3]. Company Overview - BrightSpring Health Services operates as a home and community-based healthcare services platform in the US, divided into two segments: Pharmacy Solutions and Provider Services [4].

Market Environment - The market is influenced by changes in monetary policies and global economic uncertainties, with sticky consumer price inflation being weighed against a softening U.S. labor market [2] - Investors are optimistic about a potential first rate cut from the Federal Reserve, with futures pricing in about 70 basis points of cuts over the next three meetings [2] - Global economic pressures are increasing, with weak factory output and retail sales data from China contributing to expectations for additional stimulus [3] - Despite these pressures, market sentiment remains strong, as evidenced by MSCI's Asia-Pacific ex-Japan index nearing four-year highs and South Korea's Kospi hitting a record [3] IPO Performance - The easing monetary policy and cautious optimism are shifting investor focus towards IPOs, with a list of the 11 best performing IPOs over the last two years being highlighted [4] - The methodology for selecting these IPOs includes only those that have issued in the last two years, ranked by their maximum growth rate since the IPO date [6] Company Highlights - **Tempus AI, Inc. (NASDAQ:TEM)**: - IPO Date: June 14, 2024 - Growth since IPO: 111.50% - Q2 2025 revenue reached $314.6 million, a 89.6% increase, driven by a 115% increase in Genomics revenue [10][11] - FDA approval for Tempus Pixel enhances its market position [9][10] - **BrightSpring Health Services, Inc. (NASDAQ:BTSG)**: - IPO Date: January 26, 2024 - Growth since IPO: 147.09% - Q2 2025 revenue of $3.1 billion, a 29% year-over-year increase, with Pharmacy Solutions revenue growing by 32% [14][15] - Analysts have raised price targets following strong performance [15] - **GRAIL, Inc. (NASDAQ:GRAL)**: - IPO Date: June 25, 2024 - Growth since IPO: 169.02% - Q2 2025 revenue of $35.5 million, an 11% increase, with strong demand for Galleri tests [18][19] - Partnerships with major health systems and positive study updates enhance outlook [18][20]

Company Overview - BrightSpring Health Services Inc. (NASDAQ:BTSG) operates as a home and community-based healthcare services platform in the US, divided into two segments: Pharmacy Solutions and Provider Services [4]. Financial Performance - In Q2 2025, BrightSpring Health reported total revenue of $3.1 billion, reflecting a 29% year-over-year growth, primarily driven by the Pharmacy Solutions segment [2][3]. - The Pharmacy Solutions segment experienced a 32% increase in revenue, reaching $2.8 billion, with infusion and specialty revenue surging by 39% to $2.2 billion and specialty scripts growing by 38% [2][3]. - The Provider Services segment contributed to growth with an 11% revenue increase to $358 million, supported by home healthcare revenue rising 17% to $185 million, rehab revenue increasing by 9% to $73 million, and personal care revenue growing by 4% to $100 million [3]. - Overall gross profit for the company increased by 20% year-over-year to $375 million [3]. Analyst Ratings - Deutsche Bank analyst Pito Chickering raised the price target for BrightSpring Health to $30 from $25 while maintaining a Buy rating on the shares [1][3].

Group 1 - BrightSpring Health Services is represented by its CEO Jon Rousseau and CFO Jennifer Phipps during the presentation [2] - Erin Wright, the health care services analyst at Morgan Stanley, is leading the discussion [1]

Summary of BrightSpring Health Services FY Conference Call Company Overview - **Company**: BrightSpring Health Services (NasdaqGS:BTSG) - **Industry**: Healthcare Services, specifically focusing on home and community healthcare, pharmacy services, and provider services Key Points and Arguments Business Mix and Strategy - BrightSpring is transitioning post-divestiture of its community living business, focusing on pharmacy and provider platforms serving home and community markets [3][4] - The company aims to deepen its geographical reach and enhance integrated care across service lines over the next 5 to 10 years [4][5] Growth Drivers - **Volume Growth**: Historically, volume growth has been above market rates, driven by quality and operational capabilities [6][7] - **Cost Efficiency**: Continuous focus on cost efficiency and lean operations is emphasized as a key growth driver [6][7] - **Accretive Acquisitions**: The company has a strong track record in M&A, with 66 out of 68 deals resulting in improved EBITDA [10][12] Financial Performance - The company targets organic and volume growth rates above 10%, with a historical CAGR of about 15% for revenue and EBITDA [7][8] - Recent performance indicates a strong demand for high ROI services, with expectations to maintain mid-teens EBITDA growth rates [8][22] M&A Strategy - BrightSpring has a robust pipeline for acquisitions, focusing on proprietary deals and integration processes to enhance operational efficiency [10][11] - Recent acquisition of Haven Hospice in Florida has exceeded initial business case expectations [11][12] Regulatory Environment - The company is well-positioned to navigate regulatory changes, particularly in Medicaid and home health care, with a focus on maintaining quality and efficiency [18][19] - BrightSpring's pharmacy services are seen as essential in the healthcare value chain, with ongoing efforts to manage potential impacts from drug pricing regulations [20][21] Pharmacy Solutions Segment - The pharmacy segment is experiencing rapid growth, with expectations of sustaining over 30% growth driven by specialty pharmacy services [23][24] - The company is focused on driving generic utilization and managing relationships with pharmaceutical manufacturers for new drug launches [33][36] Provider Services Segment - Home health, hospice, and rehab services are expected to continue growing in double digits, with a focus on operational execution and market share gains [41][45] - Personal care services are viewed as steady growth opportunities, contributing to overall business stability [43][46] Labor and HR Strategy - BrightSpring emphasizes strong HR practices, with improved retention rates and ongoing investments in employee benefits and training [48][49] - The company is exploring automation and AI to enhance operational efficiency and reduce reliance on labor as it scales [49][50] Future Outlook - The company anticipates continued momentum in specialty pharmacy, infusion services, and home health care, with a consistent focus on growth drivers established in previous years [51][52] Additional Important Insights - The company is optimistic about the future of its infusion business, which is expected to grow significantly compared to historical performance [51][52] - BrightSpring's commitment to quality and operational excellence is seen as a critical factor in maintaining competitive advantages in the healthcare market [22][24]

Core Viewpoint - BrightSpring Health Services, Inc. (BTSG) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is based on the consensus measure of EPS estimates from sell-side analysts, reflecting the company's changing earnings picture [2]. - The Zacks rating upgrade for BrightSpring Health Services suggests an improved earnings outlook, likely leading to a favorable impact on its stock price [4][6]. Impact of Earnings Estimates on Stock Prices - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [5]. - Institutional investors often adjust their valuations based on earnings estimates, which can lead to significant stock price movements due to large transactions [5]. Performance of Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of BrightSpring Health Services to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [11]. Earnings Estimate Revisions for BrightSpring Health Services - For the fiscal year ending December 2025, BrightSpring Health Services is expected to earn $0.94 per share, with no year-over-year change [9]. - Over the past three months, the Zacks Consensus Estimate for the company has increased by 13.6%, reflecting a positive trend in earnings estimates [9].

Core Insights - BrightSpring Health Services reported strong Q2 2025 results with GAAP revenue of $3,148 million, exceeding analyst estimates of $2,989.69 million, and adjusted EPS of $0.22, surpassing the estimate of $0.19, marking a 266.7% increase year-over-year [1][2][5] Financial Performance - Revenue grew 29.1% year-over-year, driven primarily by the Pharmacy Solutions segment, which reported revenue of $2,790 million, up 32% [5][6] - Adjusted EBITDA rose 28.8% to $143 million, reflecting effective cost management despite slower gross profit growth of 20.2% [6][7] - Net income from continuing operations remained flat at $8.5 million, indicating ongoing cost pressures, with significant non-cash items impacting profitability [7] Business Strategy - BrightSpring focuses on integrated pharmacy and home-based clinical care, serving over 450,000 patients and filling more than 41 million prescriptions in 2024 [3][4] - The company emphasizes operational excellence, patient satisfaction, and regulatory compliance as critical success factors [4] Service Offerings - Pharmacy Solutions is the largest service line, including specialty pharmacy products and home infusion therapies, with a 32% growth in specialty script volume [10] - Provider Services, which includes home health care and rehabilitation, also saw positive revenue growth and maintained high patient satisfaction [11] Regulatory Environment - The company is monitoring regulatory risks related to drug pricing and reimbursement rates, preparing for potential changes in 2026 [13] Outlook and Guidance - Management raised full-year 2025 revenue guidance to $12,200 million to $12,600 million and adjusted EBITDA guidance to $590–$605 million, attributing increases to strong pharmacy volume and operational gains [14]

Financial Data and Key Metrics Changes - BrightSpring's total revenue for Q2 2025 was $3,100,000,000, representing a 29% year-over-year growth, while adjusted EBITDA grew by 29% to $143,000,000 [9][30] - The EBITDA margin remained flat at 4.5% compared to the same quarter last year [9] - The company has increased its 2025 revenue and adjusted EBITDA guidance by $20,000,000, with adjusted EBITDA now expected to be between $590,000,000 and $605,000,000 [10][34] Business Line Data and Key Metrics Changes - Pharmacy Solutions revenue grew by 32% year-over-year to $2,800,000,000, with adjusted EBITDA also increasing by 32% [27][31] - Provider Services revenue was $358,000,000, reflecting an 11% growth year-over-year, with home health care revenue growing by 17% [30][16] - Specialty and Infusion business revenue grew by 39% year-over-year, driven by strong service levels and patient satisfaction [14][27] Market Data and Key Metrics Changes - The average daily census in home health care grew by 6% year-over-year, with home health and hospice census growth of 10% [17] - The company reported a 99% patient satisfaction score in rehab care and a 98% timely initiation of care in home health [12][17] - The company has a leading 98% dispense accuracy in home and community pharmacy services [12] Company Strategy and Development Direction - BrightSpring is focused on disciplined growth, leveraging its scale and best practices while investing in areas that enhance operational efficiencies [8][11] - The company aims to continue expanding its specialty pharmacy services, particularly in rare and complex disease therapies, with expectations of 16 to 18 additional launches over the next 12 to 18 months [14][78] - The divestiture of the Community Living business is expected to close in Q4 2025, which will allow the company to focus on its core operations [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued growth across all segments, particularly in infusion and home health services, driven by operational efficiencies and favorable market conditions [51][52] - The company anticipates that home health rates will improve in the future, despite current challenges [23][63] - Management highlighted the importance of maintaining high-quality care and patient satisfaction as key drivers of growth [11][19] Other Important Information - The company reported a net debt of approximately $2,500,000,000 with a leverage ratio of 3.6 times, aiming to reduce this to 2.0 to 2.5 times in the long term [32][57] - BrightSpring's operational cash flow is expected to exceed $300,000,000 in 2025, providing flexibility for future growth initiatives [32][56] Q&A Session Summary Question: Can you discuss the infusion performance in the quarter? - Management noted that the infusion business had its best quarter in a long time, with expectations for continued growth driven by new leadership and operational improvements [39][40] Question: What factors contributed to the increase in full-year guidance? - Management indicated that higher margins and continued momentum across the company, particularly in the provider segment, contributed to the raised guidance [50][51] Question: Can you provide insights on the growth in the home health business? - Management stated that the home health business is growing steadily, with expectations for improved rates in the future, despite current challenges [63][62] Question: How sustainable is the growth in specialty pharmacy? - Management expressed confidence in the sustainability of growth in specialty pharmacy, driven by strong service levels and ongoing investments [70][71] Question: What is the outlook for M&A activity? - Management indicated a focus on small tuck-in acquisitions while awaiting the outcomes of larger divestitures, maintaining a strong cash position for future opportunities [56][57]